Abstract
2/2012
vol. 7
Original paperTranscatheter aortic valve implantation – single center experience
Przegląd Kardiodiabetologiczny 2012; 7 (2): 103–109
Online publish date: 2012/12/09
Introduction: Transcatheter aortic valve implantation (TAVI) is alternative treatment for high risk patients with severe, symptomatic aortic stenosis. The TAVI procedures are associated with good immediate and long-term outcomes.
Aim: To determine the success, complications, and survival of patients after TAVI during hospitalization in single center.
Material and methods: A cohort of 22 patients (age 79.7 years, logistic Euroscore 23.2) with severe aortic stenosis underwent TAVI procedures. The approach was femoral in 16 patients and transapical in 6 patients.
Results: Procedural success was achieved in 21 patients (95%). AVA and Pmax before and after the procedure were respectively: 0.65 ±0.1 cm2, 99.1 ±27.1 mm Hg and 2.5 ±0.4 cm2, 15.8 ±4.4 mm Hg. Hospital mortality was 9% (2/22). One patient (with biscupid valve) died on 27 day after cardiosurgery due to aortic dissection resulting from shifting CoreValve to ascending aorta. One patient died after tamponade and multi-organ failure 4 days after procedure. During hospitalization there was no severe aortic regurgitations, strokes, myocardial infarctions and contrast induced nephropathies (excluding patients who died, nephropathy as a component of multi-organ failure).
Conclusions: Transcatheter aortic valve implantation procedures in high risk patients not qualified for surgery is efficacious method of treatment for severe, symptomatical aortic stenosis.
Aim: To determine the success, complications, and survival of patients after TAVI during hospitalization in single center.
Material and methods: A cohort of 22 patients (age 79.7 years, logistic Euroscore 23.2) with severe aortic stenosis underwent TAVI procedures. The approach was femoral in 16 patients and transapical in 6 patients.
Results: Procedural success was achieved in 21 patients (95%). AVA and Pmax before and after the procedure were respectively: 0.65 ±0.1 cm2, 99.1 ±27.1 mm Hg and 2.5 ±0.4 cm2, 15.8 ±4.4 mm Hg. Hospital mortality was 9% (2/22). One patient (with biscupid valve) died on 27 day after cardiosurgery due to aortic dissection resulting from shifting CoreValve to ascending aorta. One patient died after tamponade and multi-organ failure 4 days after procedure. During hospitalization there was no severe aortic regurgitations, strokes, myocardial infarctions and contrast induced nephropathies (excluding patients who died, nephropathy as a component of multi-organ failure).
Conclusions: Transcatheter aortic valve implantation procedures in high risk patients not qualified for surgery is efficacious method of treatment for severe, symptomatical aortic stenosis.
Keywords
aortic stenosis, transcatheter aortic valve implantation, balloon aortic valvuloplasty, femoral and transapical approach